An open-label phase II trial evaluating the efficacy and safety of neoadjuvant EndoTAG®-1 in combination with paclitaxel in patients with HER2-negative high-risk breast cancer.
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2014
At a glance
- Drugs Paclitaxel (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 14 Jun 2013 Planned number of patients changed from 20 to 18 as reported by ClinicalTrials.gov.
- 16 May 2013 Status changed from active, no longer recruiting to completed, as reported by a Medigene AG media release.